Hyperhomocysteinemia and other thrombophilic risk factors in 26 patients with cerebral venous thrombosis

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

Despite the continuous description of new conditions pre-disposing for cerebral venous thrombosis (CVT), no apparent cause is found in about 30% of cases. Hyperhomocysteinemia (hyper-Hcy) is an established risk factor for deep venous thrombosis and stroke but has not been clearly associated with increased risk of CVT. We assessed the prevalence of hyper-Hcy and other thrombophilic risk factors in a population of 26 consecutive patients with non-pyogenic CVT, by review of a prospectively maintained database. The prevalences of hyper-Hcy and prothrombin G20210A, factor V G1691A and methylenetetrahydrofolate reductase (MTHFR) C677T mutations in these patients were compared with those in 100 healthy controls and 100 patients with cerebroarterial disease. The prevalence of hyper-Hcy was greater in patients with CVT (10/26, 38.5%) than healthy controls (13/100; OR 4.18, 95% CI 1.58-11.16) and comparable with that in patients with cerebroarterial disease (42/100). No significant differences were found in the prevalences of prothrombin or MTHFR mutation. No factor V mutation was found. Our findings indicate that hyper-Hcy is associated with an increased risk of CVT. Additional prospective cohort studies on large series of patients are required to clarify the time relationship between hyper-Hcy and the thrombotic event.

Original languageEnglish
Pages (from-to)405-409
Number of pages5
JournalEuropean Journal of Neurology
Volume11
Issue number6
DOIs
Publication statusPublished - Jun 2004

Fingerprint

Intracranial Thrombosis
Hyperhomocysteinemia
Venous Thrombosis
Methylenetetrahydrofolate Reductase (NADPH2)
Prothrombin
Mutation
Factor V
Cohort Studies
Stroke
Databases
Prospective Studies
Population

Keywords

  • Cerebral venous thrombosis
  • Hyperhomocysteinemia
  • Leiden factor
  • Methylenetetrahydrofolate reductase
  • Prothrombin

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Cite this

@article{016c01090a26437992c9e25724b3763f,
title = "Hyperhomocysteinemia and other thrombophilic risk factors in 26 patients with cerebral venous thrombosis",
abstract = "Despite the continuous description of new conditions pre-disposing for cerebral venous thrombosis (CVT), no apparent cause is found in about 30{\%} of cases. Hyperhomocysteinemia (hyper-Hcy) is an established risk factor for deep venous thrombosis and stroke but has not been clearly associated with increased risk of CVT. We assessed the prevalence of hyper-Hcy and other thrombophilic risk factors in a population of 26 consecutive patients with non-pyogenic CVT, by review of a prospectively maintained database. The prevalences of hyper-Hcy and prothrombin G20210A, factor V G1691A and methylenetetrahydrofolate reductase (MTHFR) C677T mutations in these patients were compared with those in 100 healthy controls and 100 patients with cerebroarterial disease. The prevalence of hyper-Hcy was greater in patients with CVT (10/26, 38.5{\%}) than healthy controls (13/100; OR 4.18, 95{\%} CI 1.58-11.16) and comparable with that in patients with cerebroarterial disease (42/100). No significant differences were found in the prevalences of prothrombin or MTHFR mutation. No factor V mutation was found. Our findings indicate that hyper-Hcy is associated with an increased risk of CVT. Additional prospective cohort studies on large series of patients are required to clarify the time relationship between hyper-Hcy and the thrombotic event.",
keywords = "Cerebral venous thrombosis, Hyperhomocysteinemia, Leiden factor, Methylenetetrahydrofolate reductase, Prothrombin",
author = "G. Boncoraglio and Carriero, {M. R.} and L. Chiapparini and E. Ciceri and E. Ciusani and A. Erbetta and Parati, {E. A.}",
year = "2004",
month = "6",
doi = "10.1111/j.1468-1331.2004.00802.x",
language = "English",
volume = "11",
pages = "405--409",
journal = "European Journal of Neurology",
issn = "1351-5101",
publisher = "Wiley-Blackwell Publishing Ltd",
number = "6",

}

TY - JOUR

T1 - Hyperhomocysteinemia and other thrombophilic risk factors in 26 patients with cerebral venous thrombosis

AU - Boncoraglio, G.

AU - Carriero, M. R.

AU - Chiapparini, L.

AU - Ciceri, E.

AU - Ciusani, E.

AU - Erbetta, A.

AU - Parati, E. A.

PY - 2004/6

Y1 - 2004/6

N2 - Despite the continuous description of new conditions pre-disposing for cerebral venous thrombosis (CVT), no apparent cause is found in about 30% of cases. Hyperhomocysteinemia (hyper-Hcy) is an established risk factor for deep venous thrombosis and stroke but has not been clearly associated with increased risk of CVT. We assessed the prevalence of hyper-Hcy and other thrombophilic risk factors in a population of 26 consecutive patients with non-pyogenic CVT, by review of a prospectively maintained database. The prevalences of hyper-Hcy and prothrombin G20210A, factor V G1691A and methylenetetrahydrofolate reductase (MTHFR) C677T mutations in these patients were compared with those in 100 healthy controls and 100 patients with cerebroarterial disease. The prevalence of hyper-Hcy was greater in patients with CVT (10/26, 38.5%) than healthy controls (13/100; OR 4.18, 95% CI 1.58-11.16) and comparable with that in patients with cerebroarterial disease (42/100). No significant differences were found in the prevalences of prothrombin or MTHFR mutation. No factor V mutation was found. Our findings indicate that hyper-Hcy is associated with an increased risk of CVT. Additional prospective cohort studies on large series of patients are required to clarify the time relationship between hyper-Hcy and the thrombotic event.

AB - Despite the continuous description of new conditions pre-disposing for cerebral venous thrombosis (CVT), no apparent cause is found in about 30% of cases. Hyperhomocysteinemia (hyper-Hcy) is an established risk factor for deep venous thrombosis and stroke but has not been clearly associated with increased risk of CVT. We assessed the prevalence of hyper-Hcy and other thrombophilic risk factors in a population of 26 consecutive patients with non-pyogenic CVT, by review of a prospectively maintained database. The prevalences of hyper-Hcy and prothrombin G20210A, factor V G1691A and methylenetetrahydrofolate reductase (MTHFR) C677T mutations in these patients were compared with those in 100 healthy controls and 100 patients with cerebroarterial disease. The prevalence of hyper-Hcy was greater in patients with CVT (10/26, 38.5%) than healthy controls (13/100; OR 4.18, 95% CI 1.58-11.16) and comparable with that in patients with cerebroarterial disease (42/100). No significant differences were found in the prevalences of prothrombin or MTHFR mutation. No factor V mutation was found. Our findings indicate that hyper-Hcy is associated with an increased risk of CVT. Additional prospective cohort studies on large series of patients are required to clarify the time relationship between hyper-Hcy and the thrombotic event.

KW - Cerebral venous thrombosis

KW - Hyperhomocysteinemia

KW - Leiden factor

KW - Methylenetetrahydrofolate reductase

KW - Prothrombin

UR - http://www.scopus.com/inward/record.url?scp=3142767412&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3142767412&partnerID=8YFLogxK

U2 - 10.1111/j.1468-1331.2004.00802.x

DO - 10.1111/j.1468-1331.2004.00802.x

M3 - Article

VL - 11

SP - 405

EP - 409

JO - European Journal of Neurology

JF - European Journal of Neurology

SN - 1351-5101

IS - 6

ER -